Shinobi Therapeutics Inc.
shinobitx.com
Regenerative Medicine
Cell & Gene Therapy
Health Care
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
201-500
employees, estimated range
Backers
3
Eight Roads, JIC Venture Growth Investments
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
Building programmable in vivo immune-cell therapies across oncology and autoimmune disease.
Advance your cell therapy with Cellipont Bioservices, a leading cell therapy CDMO, offering tailored development, analytics, and cGMP…
Constellation® is an automated cell therapy manufacturing platform that enables scalable, flexible production without therapy redevelopment…
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Kyoto University Innovation CapitalVia a fund
JIC Venture Growth InvestmentsVia a fund
Eight RoadsVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression
Allogeneic cell therapeutics for cancer therapy or regenerative medicine are susceptible to antibody-mediated killing, which diminishes their efficacy. Here we report a strategy to protect cells from antibody-mediated killing that relies on engineered ove
Read more
Report
Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells
Avoiding the immune rejection of transplanted T cells is central to the success of allogeneic cancer immunotherapies. One solution to protecting T-cell grafts from immune rejection involves the deletion of allogeneic factors and of factors that activate c
Read more
Report
A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy
Clinical successes demonstrated by chimeric antigen receptor T-cell immunotherapy have facilitated further development of T-cell immunotherapy against wide variety of diseases. One approach is the development of "off-the-shelf" T-cell sources. Technologie
Read more
Report
Japan's Bioeconomy Breakthrough: Turning World-Class Science into Global Business
In Japanese, the word
Read more
Report